The company Clever Leaves confirmed a commercial export alliance to meet the medical cannabis needs of the European market. This deal is but one of many powering the international expansion of the cannabis industry, where growing demand is increasingly being met by innovative and determined Colombian producers in collaboration with government institutions and international investors.
On the morning of Wednesday, March 17, the Colombian company Clever Leaves announced the confirmation of a commercial alliance with the European pharmaceutical company Ethypharm. The deal covers the sale of medical cannabis products to be exported from Colombia.
Want to know more about the cannabis being exported out of Colombia? Need to stay up to date on the global movements of hemp and hemp products, keep up with the cannabis news on out companion HEMP.IM app.
The company behind Colombian cannabis exports:
Clever leaves is an authorized producer of hemp extracts and medical cannabis of pharmaceutical quality that, within the country, has the certification of Good Manufacturing Practices (GMP) granted by the National Institute of Food and Drug Surveillance of Colombia (Invima), and internationally has the Certification of Good Agricultural and Collection Practices (GACP) by the Control Union Medical Cannabis Standard (CUMCS).
The commercial alliance will allow the company to sell medical cannabis extracts from Colombia under the European Union’s Good Manufacturing Practices (EU-GMP) certification. The initial offer of products to be exported includes formulas with high CBD content, high THC content and balanced CBD and THC formulas that meet the regulatory requirements of the German market.
Andrés Fajardo, president of Clever Leaves, highlighted the company’s recognition for having the highest quality standards in the product they offer:
‘The company has once again demonstrated the quality of its operation and the rigor of its procedures, evidencing the talent and dedication of a highly trained multidisciplinary team. Patients around the world can be assured that Clever Leaves’ raw materials have internationally recognized procedures that are free of heavy metals or agrochemicals.”
According to Kyle Detwiler, CEO of Clever Leaves, the alliance will allow the Colombian company to help improve the health of international patients, in this case in Europe Arguing that parterning with Ethypharm, the well regarded European pharmaceutical company, is a step towards their vision of providing patients with market-leading medical cannabis products.
“Clever Leaves’ focus on EU GMP production of high quality cannabis, as well as our international supply chain, allows us to develop, produce and distribute products to our target markets, which will have a significant impact on patients’ treatments.”
For his part, Bertrand Deluard, CEO of Ethypharm, spoke of the need to treat diseases and pains of citizens with an alternative not medically covered in the market. Their company is determined to improve peoples’ lives by partnering with phamacists.
“Today, providing medical cannabis to patients who are not relieved by current treatments is an answer to a clear unmet medical need.” He also stated that “This groundbreaking medical cannabis collaboration with Clever Leaves is a good example of how Ethypharm has developed new ways to provide patients with the care they need.”
Colombia sends first commercial export of medical cannabis to Mexico first
Another Colombian company, Pideka, announced on March 10 that, for the first time it would be shipping a commercial grade medical cannabis to mexica. The produce, containing THC, was cultivated at their indoor facility in Tocancipá. This new export country could represent a market of US$20 billion, since it has close to one million potential patients suitable for treatment with medical cannabis.
They took this important step hand in hand with ProColombia and other entities of the Colombian government. These institutions helped “open the door to consolidate our position in a market as important as the Mexican market, to sell medical cannabis oil with THC to the public or private sector,” said Borja Sanz de Madrid, president of the company in Colombia.
Pideka is a company created in Colombia with Canadian, Spanish, North American and Latin American investment for the production of cannabis pharmaceuticals.
Paradoxically, the covid-19 pandemic caused the use of cannabis and its industry to increase in its use and, respectively, in its production. The countries that noticed this increase were mainly Canada and the United States. Increasingly, much of the medical cannabis arriving in these countries is grown in Colombia and sold for export.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Infobae, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.